Prevent immunogenicity surprises
in the clinic.
Who We Are
Fearless Science.
EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, we employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into candidate immunogenicity, ensuring the effectiveness and safety of our clients’ products.
12M+
sequences analyzed
17
of the 20 top pharmaceutical companies served
500+
industry, agency, & academic collaborators
26
years experience
220+
peer-reviewed publications
News
The Amsterdam Immunogenicity and Tolerance Seminar – 2024
Join us in Amsterdam! The 10th annual Amsterdam...
Westin Immunogenicity Seminar & Computational Vaccinology Symposium- 2024
For the first time, EpiVax is hosting two...
The Amsterdam Immunogenicity and Tolerance Seminar – 2024
Join us in Amsterdam! The 10th annual Amsterdam...
Westin Immunogenicity Seminar & Computational Vaccinology Symposium- 2024
For the first time, EpiVax is hosting two...
Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ --...